B. Aigret

发表

Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial

F. Markowetz, T. Bray, Shruti Singh, 2020, The Lancet.

Barrett’s oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux

S. Smith, P. Sasieni, M. O’Donovan, 2018, BMC Cancer.

Selective LC-MS/MS method for the identification of BMAA from its isomers in biological samples

L. Ilag, Z. Spacil, Liying Jiang, 2012, Analytical and Bioanalytical Chemistry.

Risk stratification of Barrett's oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study.

R. Haidry, L. Lovat, P. Sasieni, 2017, The lancet. Gastroenterology & hepatology.

Evaluation of a Minimally Invasive Cell Sampling Device Coupled with Assessment of Trefoil Factor 3 Expression for Diagnosing Barrett's Esophagus: A Multi-Center Case–Control Study

Sarmed S. Sami, S. Sami, R. Haidry, 2015, PLoS medicine.

High-dose oral vitamin D supplementation and mortality in people aged 65-84 years: the VIDAL cluster feasibility RCT of open versus double-blind individual randomisation.

J. Peto, P. Sasieni, C. Gilham, 2020, Health technology assessment.

Cohort study : Risk stratification of Barrett ’ s oesophagus using a non-endoscopic sampling method coupled with a biomarker panel

Novelli, Pradeep, R. Haidry, 2016 .

Asymmetric Synthesis of 1-Aza-4-deoxypicropodophyllotoxin

L. Van Meervelt, W. D. De Borggraeve, J. Jacobs, 2013, Synlett.

Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial

F. Markowetz, T. Bray, L. Lovat, 2020, The Lancet.